Alliance Pharma Regulatory News (APH)

18 May 2006 07:02

Alliance Pharma PLC18 May 2006 For immediate release 18 May 2006 ALLIANCE PHARMA PLC ("Alliance Pharma" or "the Company") Further expansion of skincare portfolio through bolt-on acquisition of Caraderm Limited Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleasedto announce that it has agreed to acquire Caraderm Limited ("Caraderm"), aNorthern Ireland company whose key asset is Dermamist, a dermatological sprayfor dry skin conditions. Based on 2005 volumes, Dermamist will add annualised sales of £108,000 and addsa further product to Alliance's growing dermatology portfolio. Alliance is paying £260,000 in cash for the entire share capital of Caraderm,under a transaction in which staff will not be transferred to Alliance. John Dawson, Alliance Pharma's Chief Executive, commented: "This latestacquisition delivers a further product to our dermatology portfolio. We gainedcritical mass in dermatology earlier this year through the acquisition of theHydromol range and we look forward to the continuing success of our skincarefranchise." For further information: Alliance Pharma plc + 44 (0) 1249 466966John Dawson, Chief ExecutiveMaddy Scott, Finance Directorwww.alliancepharma.co.uk Buchanan Communications + 44 (0) 20 7466 5000Mark Court/Lisa Baderoon/Rebecca Dietrich Notes to editors About Alliance PharmaAlliance Pharma, founded in 1996, is an AIM listed speciality pharmaceuticalcompany based in Chippenham, Wiltshire, UK. The company has a strong trackrecord of acquiring the rights to established niche brands and owns, or shares,the rights to 30 branded pharmaceutical products and continues to exploreopportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to UK and International pharmaceuticalwholesalers which service both hospital and retail pharmacies with theirprescription requirements. Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor forthe induction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange